This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Hong Kong Baptist University. Active years: 2016-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2017
Title: Innovations by Liang Feng Liu
Introduction
Liang Feng Liu is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of pharmaceuticals and health supplements. With a total of 2 patents, his work focuses on innovative treatments for neurodegenerative diseases.
Latest Patents
One of his latest patents is titled "Synthesis of autophagy inducing compound and the uses thereof." This invention relates to a composition comprising a compound of formula CB6 or CB8, along with a pharmaceutically-acceptable carrier or solvent. It is designed to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The invention also outlines a method for treating these diseases by administering a therapeutically-effective amount of the compound to the subject in need. Another significant patent involves a herbal composition that compensates for the Aβ increasing effects of existing treatments. This invention presents a more potent treatment for neurodegenerative diseases without the associated β-amyloid increasing effect.
Career Highlights
Liang Feng Liu is affiliated with Hong Kong Baptist University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating serious health conditions.
Collaborations
Liang Feng Liu collaborates with Ju Xian Song, contributing to the development of innovative solutions in the pharmaceutical field.
Conclusion
Liang Feng Liu's contributions to the field of pharmaceuticals and health supplements highlight his commitment to addressing critical health challenges. His innovative patents reflect a dedication to improving treatments for neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
